Chronic liver disease
Conditions
Interventions
Autoimmune liver disease group:None
Normal control group:None
Sponsors
Zhongshan Hospital Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Normal control group patients: (1).Chinese citizens aged 18 to 85 years old; (2).with a normal BMI range of (18.5-23.9 kg/m^2), and imaging or blood biomarkers/scores, or liver histological tests indicating normal liver function; (3).excluding chronic liver diseases such as metabolic-related fatty liver disease, hyperlipidemia, diabetes, and viral hepatitis; 2. MAFLD group patients: (1).Chinese citizens aged 18 to 85 years old; (2).meeting the diagnostic criteria for metabolic-related fatty liver disease: presence of hepatic steatosis in imaging or blood biomarkers/scores, liver histological tests, and meeting one of the following three criteria: being overweight/obese (BMI >=23 kg/m^2), type 2 diabetes (T2DM), or metabolic disorders. Metabolic disorder is defined as meeting at least two of the following abnormalities: 1) Waist circumference >=90/80cm (male/female); 2) Blood pressure >=130/85mmHg or medication therapy; 3) Plasma triglycerides >=150mg/dl(>=1.70mmol/L) or special drug therapy; 4) Plasma high-density lipoprotein cholesterol: male =2.5; 7) Plasma C-reactive protein level>2 mg/L; 3. Hepatitis B diagnosis group: 1).Chinese citizens aged >=18 years and =18 and <=85 years; (2). According to the diagnosis and treatment guidelines for autoimmune hepatitis.
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1.Age 85 years; 2.Pregnant patients; 3.Patients who have undergone or are undergoing systemic chemotherapy, or those who have undergone TACE surgery; patients with tumors in the liver segment to be sampled; 4.Other types of viral hepatitis, alcohol-related fatty liver disease (past 12-month alcohol intake equivalent to >=30g/d for males, >=20g/d for females), and drug-induced liver injury; 5.Patients refusing to sign informed consent forms; 6.Patients at significant bleeding risk during biopsy (platelet count <50%).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| areas under ROC; | — |
Countries
China
Contacts
Public ContactXu Huixiong
Zhongshan Hospital Fudan University
Outcome results
None listed